Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 6/20 | 0.71 |
| ▸ | MMP13 | P45452 | 3/20 | 0.71 |
| ▸ | MMP12 | P39900 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 3/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100698 | 0.96 | ADAM17 (0.77) | ADAM17MMP13MMP12KDM4EMMP2 | |
| Trifluoroacetic Acid SCHEMBL6099184 | 0.88 | ADAM17 (0.61) | ADAM17MMP13MMP12KDM4EMMP2 | |
| Trifluoroacetic Acid SCHEMBL6102661 | 0.85 | ADAM17 (0.57) | ADAM17MMP13MMP12MMP2MMP3 | |
| SCHEMBL5407548 | 0.83 | ADAM17 (1.00) | ADAM17MMP13MMP12MMP2MMP3 | |
| SCHEMBL5416972 | 0.83 | ADAM17 (1.00) | ADAM17MMP13MMP12MMP2MMP3 | |
| Trifluoroacetic Acid SCHEMBL6099339 | 0.82 | ADAM17 (0.51) | ADAM17MMP13MMP12MMP2MMP3 | |
| Trifluoroacetic Acid SCHEMBL6102383 | 0.80 | ADAM17 (0.66) | ADAM17MMP13MMP12MMP2MMP3 | |
| Trifluoroacetic Acid SCHEMBL5887714 | 0.80 | ADAM17 (0.57) | ADAM17MMP13MMP12MMP2MMP3 | |
| Trifluoroacetic Acid SCHEMBL6100695 | 0.79 | ADAM17 (0.52) | ADAM17MMP13MMP12MMP2MMP3 | |
| SCHEMBL6101272 | 0.79 | ADAM17 (0.53) | ADAM17MMP13MMP12MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101883-B2 | Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20030229081-A1 | Uracil derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229081-A1 | Uracil derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and matrix metalloproteinases | UNG, IDUA, TNF | ADAM17 26/4885MMP13 29/4885MMP12 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.